The challenge highlighted by strategies such as afatinib plus cetuximab is the remarkable ability of HNSCC cells to evade treatment through compensatory signaling, including upregulation of HER2/HER3 or alternative RTKs such as MET and IGF-1R [88,89]. This evidence concerns the gene MET and head and neck squamous cell carcinoma.